JULIE NANGIA to Middle Aged
This is a "connection" page, showing publications JULIE NANGIA has written about Middle Aged.
Connection Strength
0.188
-
Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer: The SCALP Randomized Clinical Trial. JAMA. 2017 02 14; 317(6):596-605.
Score: 0.030
-
VEMORA: Vaginal Estrogen versus non-hormonal MOisturizer in women Receiving Aromatase inhibitors: a randomized, controlled trial. Breast Cancer Res Treat. 2026 Jul 30; 218(2).
Score: 0.015
-
Patient-reported outcomes from the TBCRC 022 study of neratinib and ado-trastuzumab emtansine for HER2-positive breast cancer brain metastases. Breast. 2026 Oct; 89:104881.
Score: 0.015
-
TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancer. ESMO Open. 2026 Apr; 11(4):106063.
Score: 0.014
-
Multilevel barriers and supportive care preferences of metastatic breast cancer patients and their caregivers: a mixed-methods analysis. Support Care Cancer. 2025 Feb 11; 33(3):177.
Score: 0.013
-
Neratinib and ado-trastuzumab emtansine for pretreated and untreated human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases: Translational Breast Cancer Research Consortium trial 022. Ann Oncol. 2024 Nov; 35(11):993-1002.
Score: 0.013
-
A mixed-methods study to inform development of a caregiver-specific problem list for cancer distress screening. Psychooncology. 2023 10; 32(10):1578-1585.
Score: 0.012
-
TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer. Clin Cancer Res. 2020 05 01; 26(9):2111-2123.
Score: 0.009
-
TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer. Clin Cancer Res. 2020 02 15; 26(4):821-827.
Score: 0.009
-
Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. Clin Breast Cancer. 2020 04; 20(2):145-151.e2.
Score: 0.009
-
Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia. Breast Cancer Res Treat. 2019 Sep; 177(2):427-435.
Score: 0.009
-
TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol. 2019 05 01; 37(13):1081-1089.
Score: 0.009
-
A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease. Cancer Prev Res (Phila). 2018 04; 11(4):203-214.
Score: 0.008
-
Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019. Clin Cancer Res. 2015 Jun 15; 21(12):2771-9.
Score: 0.007
-
TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer. Clin Cancer Res. 2015 Jun 15; 21(12):2722-9.
Score: 0.007
-
Jejunal intussusception due to malignant phyllodes tumor of the breast. Clin Breast Cancer. 2012 Jun; 12(3):219-21.
Score: 0.005
-
Idiopathic hemophagocytic syndrome with a fulminant clinical course. Clin Adv Hematol Oncol. 2008 Aug; 6(8):587-90.
Score: 0.004